Taletrectinib is now a preferred treatment for advanced ROS1-positive NSCLC, effective in first-line and subsequent therapies, especially for brain metastases. TRUST-I and TRUST-II trials showed high ...
HER2 mutations involve genetic alterations, while HER2 expression refers to protein overexpression, both impacting NSCLC treatment strategies. Fam-trastuzumab deruxtecan-nxki and ado-trastuzumab ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and ...
Black Diamond Therapeutics’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor ...
Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
Final analysis of RATIONALE-315 demonstrates clear overall survival benefit in perioperative setting in resectable non-small cell lung cancer Broad EU label with nine approved indications in solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback